14:45 – 15:00
Dafna KNANI, Biotechnology Engineering
My current research focuses on molecular modeling of materials and biomaterials. Some of my research topics are: Molecular modeling of peptide amphiphiles ; Simulation of gelatine-alginate based bioadhesives ; Simulation of novel soy protein-based structures for tissue regeneration applications ; Molecular modeling of CO2 plasticization and sorption onto absorbable polyesters; Computational design of novel plasticizers for Nylon; In-silico studies of organo- and hydrogelators.
15:00 – 15:15
Amal TOUBI, Biotechnology Engineering
The research is in the field of biotechnology and food science, with an emphasis on the extraction of natural compounds, from sources such as mushrooms and plants. In the current research work we investigate the potential application of chlorophyll pigments, that were extracted from plants and encapsulated in food grade matrix. The properties of the microcapsules were determined and their application in food products was also investigated.
15:15 – 15:30
Sivan KLAS, Biotechnology Engineering
My research focuses on developing technologies to extract valuable minerals from brine produced during the desalination of groundwater. This enables sustainable desalination and supports the aquaculture industry. A pilot facility treats over 100 cubic meters of water, produces more than 30 tons of purified limestone annually, and supports the cultivation of over 6 tons of sea bream (Denis) per year
15:30 – 15:45
Gilad ALFASSI, Biotechnology Engineering
My research focuses on plant waste and biopolymers, using chemical engineering, biochemistry, and biotechnology to develop processes for producing biodiesel, bioplastics, and other materials. I work with bioreactors and innovative emulsion particles, with an emphasis on sustainability, resource recycling, and reducing environmental impact.
15:45 – 16:00
Idit GOLANI, Biotechnology Engineering
My research focuses on pharmacological treatment of Central Nervous System (CNS) disorders. One direction involves brain-targeting drugs by conjugating them to a protein expressed on the blood-brain barrier, aiming to enhance penetration and efficacy and minimize side effects. The second direction is the examining for potential drugs with novel mechanism- blocking the ErbB pathway, for treating psychiatric symptoms, such as anxiety and depression, using in vitro and in vivo systems